RT

Rachel Tsunemoto Hislop

Principal, Director of Research at Two Bear Capital

San Diego, California

Overview 

Rachel Tsunemoto Hislop is currently serving as the Principal and Director of Research at Two Bear Capital in San Diego, California. With a background in neuroscience and a Ph.D. from UC San Diego, she has held roles such as Board Observer at Abilita Therapeutics and Novoron Bioscience, as well as a Medical Science Liaison at Acorda Therapeutics, showcasing a diverse career in both research and investment within the biotech sector.

Work Experience 

  • Principal, Director of Research

    2024 - Current

  • Principal

    2020 - 2024

Two Bear Capital invests in early stage companies with disruptive innovations.

  • Board Observer

    2022 - 2024

Abilita Therapeutics, Inc. is a biotechnology company.

  • Board Observer

    2021 - 2024

Biotechnology company developing pharmaceutical therapies for nerve regeneration in the central nervous system.

Raised $16,165,350.00 from Two Bear Capital and Two Bear Capital.

  • Medical Science Liaison

    2017 - 2020

  • Stem Cell and Molecular Biology Researcher

    2016 - 2017

    Ph.D. researcher working with Dr. Lawrence Goldstein and Dr. Samuel Pfaff

Moores Cancer Center is the only National Cancer Institute-designated Comprehensive Cancer Center in the San Diego region.

  • Science Communicator

    2013 - 2016

  • Neuroscience Ph.D. Candidate and Research Associate

    2010 - 2016

    Neuroscience Ph.D. student (graduated March 2016) working with Dr. Kristin Baldwin (The Scripps Research Institute).

  • Undergraduate Research Assistant

    2008 - 2009

    Undergraduate student working with Dr. Li-Huei Tsai.

  • Summer Research Intern

    2007 - 2007

Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.

Raised $5,586,000.00 from Private Capital Advisors.

Articles About Rachel

Relevant Websites